Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Best Pract Res Clin Haematol. 2020 Dec;33(4):101225. doi: 10.1016/j.beha.2020.101225. Epub 2020 Nov 18.
Outcomes for relapsed and refractory acute lymphoblastic leukemia (ALL) remain poor. With the advent of targeted monoclonal antibodies and antibody constructs, these outcomes have been significantly improved both in the frontline and salvage setting. These targets include a bispecific antibody that targets both CD3 and CD19, known as blinatumomab, as well as a conjugated antibody that targets CD22, known as inotuzumab ozogamicin. These agents have been thoroughly studied and successively approved for use as monotherapy, however, more recently they have been incorporated in combination or sequentially with cytotoxic chemotherapy. In this chapter, we will discuss the role that these monoclonal antibodies play as monotherapy and in combination in the treatment of ALL in the salvage setting, and how they continue to transform the treatment management of relapsed and refractory ALL.
复发和难治性急性淋巴细胞白血病（ALL）的治疗结果仍然较差。随着靶向单克隆抗体和抗体构建物的出现，这些结果在一线和挽救治疗环境中都得到了显著改善。这些靶点包括一种双特异性抗体，既能靶向 CD3，又能靶向 CD19，称为blinatumomab，以及一种靶向 CD22 的共轭抗体，称为 inotuzumab ozogamicin。这些药物已经经过了充分的研究，并相继被批准作为单一疗法使用，但最近它们已被纳入联合或序贯细胞毒性化疗。在本章中，我们将讨论这些单克隆抗体作为单一疗法以及在挽救治疗环境中联合应用于 ALL 治疗的作用，以及它们如何继续改变复发和难治性 ALL 的治疗管理。
